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Fig. 1: DPVis consists of seven view areas: (A) Static Variables Distribution View shows distribution over static variables; (B)
Panel for Observed Attributes summarizes characteristics of disease states estimated by a hidden Markov model; (C) Panel for
State Transitions shows heterogeneous disease progression patterns of multiple subjects; (D) Frequently Occurring State Transition
Pattern View summarizes frequently occurring state sequential patterns; (E) Subject List View shows subjects’ visits over time; (F)
State Sequence Query Builder enables users to build and refine cohorts; (G) Cohort View allows users to save and load intermediate
results. Users can toggle between multiple views in (B) and (C) depending on their analytic goals.
Abstract— Clinical researchers use disease progression modeling algorithms to predict future patient status and characterize
progression patterns. One approach for disease progression modeling is to describe patient status using a small number of states
that represent distinctive distributions over a set of observed measures. Hidden Markov models (HMMs) and its variants are a class
of models that both discover these states and make predictions concerning future states for new patients. HMMs can be trained
using longitudinal observations of subjects from large-scale cohort studies, clinical trials, and electronic health records. Despite the
advantages of using the algorithms for discovering interesting patterns, it still remains challenging for medical experts to interpret model
outputs, complex modeling parameters, and clinically make sense of the patterns. To tackle this problem, we conducted a design study
with physician scientists, statisticians, and visualization experts, with the goal to investigate disease progression pathways of certain
chronic diseases, namely type 1 diabetes (T1D), Huntington’s disease, Parkinson’s disease, and chronic obstructive pulmonary disease
(COPD). As a result, we introduce DPVis which seamlessly integrates model parameters and outcomes of HMMs into interpretable,
and interactive visualizations. In this study, we demonstrate that DPVis is successful in evaluating disease progression models, visually
summarizing disease states, interactively exploring disease progression patterns, and designing and comparing clinically relevant
subgroup cohorts by introducing a case study on observation data from clinical studies of T1D.
Index Terms—Disease Progression Model, Hidden Markov Model, Diabetes, Huntington’s Disease, Parkinson’s Disease, Interpretability
1 INTRODUCTION
Clinical researchers and physician scientists use disease progression
models to characterize patterns of disease development and to predict
future patient status. Investigators use clinical studies to derive accurate
disease prognosis and to understand how each patient’s characteristic
interplay with the course of disease. This knowledge can ultimately
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lead to early detection of diseases and precision care for each patient
at appropriate points in time. Large-scale prospective clinical studies
make it possible for clinicians to collect serial lab tests, self-reports,
and treatments over a long period of time. A major challenge is to
find appropriate methods that distill temporal sequences of various
measures into clinically useful insights.
One approach for modeling disease progression is to describe a pa-
tient’s clinical course as a series of transitions between a small number
of states, with each state describing a co-occurring pattern of observed
measures or symptoms [68]. The states, commonly referred to as latent
or hidden variables, are not directly observed but rather must be dis-
covered from the data. Hidden Markov models (HMMs) are a class of
unsupervised, statistical models that allow for discovering such latent
states, understanding characteristics of progression patterns with the
associated observed variables for corresponding states, and predicting a
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patient’s future states. Since HMMs can be trained on longitudinal pa-
tient data from large-scale clinical studies and electronic health records
(EHRs), HMMs have been successfully applied to capture heteroge-
neous disease progression patterns in various disease, such as chronic
obstructive pulmonary disease [68] and Huntington’s disease [63].
Despite the potential usefulness of HMMs for understanding dis-
ease progression patterns, it remains challenging for domain experts
to make sense of the models and to derive clinically useful insights.
Goals of data exploration include discovery of heterogeneous disease
progression patterns, observation of interactions between such patterns
and patients’ characteristics, and testing and refining hypotheses for
multiple cohorts in an adhoc manner. HMMs produce relevant outputs
that can potentially fulfill these needs, but it is often difficult for do-
main users to gain useful understanding of clinical observation data
by aggregating and connecting various statistical outcomes without
the help of interactive visualization systems. Though prior studies
introduced inspiring visualization techniques that can partially solve
these problems, no system yet integrates such techniques into a visual
analytic solution for disease progression modeling using HMMs.
Thus, our goal is to develop a visual analytic system that integrates
HMM outcomes on observational data from clinical studies with var-
ious visualization techniques. To achieve this goal, we conducted a
design study with domain experts, including physicians, statisticians,
and visualization experts, to explore the design space of interactive
visualization methods. In this process, we summarized tasks and re-
quirements of the users, and extracted outcomes that are relevant to
meet the task goals by using HMMs trained on observational data from
birth-cohort studies of Type 1 Diabetes (T1D) and EHRs of Parkinson’s
disease. As a result, we introduce DPVis, which seamlessly integrates
outcomes of HMMs into interactive visualizations.
The following three items summarize our main contributions:
1. We developed DPVis that integrates HMMs with interactive vi-
sualizations for discovering disease progression patterns from
longitudinal observational data collected from clinical studies.
2. Our design study examines tasks of disease progression re-
searchers and provides various ways to visualize the statistical
outcomes of HMMs for supporting these tasks.
3. We provide a case study that demonstrates the usefulness of DPVis
for domain experts to make sense of HMMs, to detect interesting
disease progression patterns, and to derive clinical insights.
In the following sections, we first review prior research on disease
progression models, HMMs, and visualization methods that are applied
to longitudinal clinical data in Section 2. Next, we introduce our
design study methods, where we conceptualize domain experts’ goals
and characteristics, introduce the datasets and the models used, and
summarize the analytic tasks and goals that domain experts seek to
perform on the data using HMMs in Section 3. In Section 4, we
describe the design of DPVis, and how the views and interactions
can help domain experts solve their tasks. In Section 5, we report a
case study, where a fictitious investigator named Amy observes 168
subjects diagnosed with T1D and derives clinically useful insights using
DPVis. We discuss the implications and lessons learned in Section 6
and provide future work in Section 7.
2 RELATED WORK
In this section, we review disease progression studies in the field of
medicine, various modeling techniques in statistics and machine learn-
ing, and visual analytic approaches in the visualization domain.
2.1 Disease Progression Research in Clinical Studies
Well-designed longitudinal studies play an important role in clinical
research because they provide rich information for tracking the progres-
sion of disease by collecting repeated measures from individuals of a
target cohort over a long period of time. Such studies are designed and
conducted with many present and future goals, such as understanding
the etiology or pathogenesis of a disease. One of the most well-known
longitudinal studies is the Framingham Heart Study, which has brought
great insights into heart disease (e.g., [26, 37]). In particular, many
studies call for research into applying suitable statistical modeling tech-
niques that can explain the mechanism of disease progressions. For
example, the Parkinson Progression Marker Initiative (PPMI) [44] is an
international observational multi-center study of Parkinson’s Disease.
PPMI established protocols that were adopted at 21 clinical sites to
provide a platform for researchers to gain common access to the data,
which includes clinical, socio-demographic, and imaging variables as
well as bio-specimens. In case of T1D, researchers seek to understand
the diverse pathways from a healthy state to the onset of disease for
both individual patients and the overall population [75]. The Type 1
Data Intelligence (T1DI) study group was established to accelerate
disease progression research by combining decades of data from birth
cohort studies conducted at various institutions around the world: 1)
Diabetes Autoimmunity Study in the Young (DAISY) [56]; 2) Diabetes
Prediction in Ska˚ne (DiPiS) [28]; 3) Diabetes Prediction and Prevention
(DIPP) [48]; and 4) Diabetes Evaluation in Washington State (DEW-
IT) [70]. We conducted a design study with clinical researchers and
statisticians who have been involved in the research groups above.
2.2 Disease Progression Modeling
Disease Progression Models (DPM) [47] include a broad class of mod-
els that use mathematical functions to quantitatively predict disease
status over time. DPM can be categorized by algorithm into systems
biology, data-driven, and semi-mechanistic models [10]. There are
many different approaches to model disease progression, including
path models [65], tree based models [11], hierarchical latent variable
models [57], Gaussian process models [42], and Bayesian networks [3].
In this study, we have chosen to focus on HMMs, a probabilistic, unsu-
pervised class of models. In an HMM, the target disease is represented
by a fixed number of typical disease states, its progression is char-
acterized by a Markov process, and the observed measures are the
manifestations of the underlying disease states. HMMs were selected
for the following reasons: (1) They are probabilistic in nature and
represent uncertainties in clinical datasets organically; this uncertainty
in state assignment is shown via posterior distributions over states. (2)
They work well with missing data, a common issue in observational
studies. (3) Users can model various kinds of progressions, such as
forward-only progression (e.g., chronic diseases), where the damage
caused by the disease is permanent and affected areas gradually lose
their functions, and backward-enabled progression, where patients can
recover from the diseases. (4) HMMs are unsupervised models that do
not require a particular outcome task. (5) They provide interpretability
by a small number of ‘states’ that are associated with multiple ob-
served variables. Examples of HMMs applied to disease progression
include [23, 38, 62, 63, 69]. HMMs are described further in Section 3.4.
2.3 Visualizations for Disease Progression Analysis and
Various Measures of Patients
In this section, we review previous studies that show inspiring examples
to tackle our problem. Prior studies have investigated various visualiza-
tion methods to represent temporal event sequences. Shneiderman and
Plaisant [59] summarize the challenges of analyzing temporal sequence
data. Several techniques were proposed to integrate sequence mining
algorithms for visualizing the summary of event sequences, including
LifeLines [52], LifeLines2 [67], EventFlow [46], and LifeFlow [72],
which allow users to visually align and explore various patterns of
multiple event sequences. Frequence [50], Care Pathway Explorer [51],
and Peekquence [34] visualize frequent event sequences mined from
the SPAM algorithm [1]. Outflow [71] and Sequence Synopsis [8] allow
users to interactively explore multiple pathways in event sequences.
These techniques allow users to steer the algorithm with interaction.
In addition, other techniques integrate automated results with user-
defined queries or criteria. TimeStitch [53], Choronodes [54], and
Coquito [29] extract frequent mining patterns using algorithms like
PrefixSpan [49], and then visualizes the sequences so that users can in-
teractively provide relevant feedback to refine the search. Eventpad [6]
and (s|qu)eries [73] allow users to build search queries using the pro-
gressive visual analytics (PVA) paradigm [61]; the idea was further
extended and implemented as the PPMT tool [55]. EventThread [22]
2
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visualizes clusters of event sequences using tensor analysis. Liu et
al. [40] and MAQUI [36] allows users to recursively explore hierarchi-
cal patterns in event sequences. E2 [21], StageMap [7], and Mathisen
and Grnbk [45] introduce a composite event sequence to aggregate pat-
terns. CoreFlow [39] and Guo et al. [20] visualize branching alternative
paths with uncertainties. IDMVis [74] allows users to fold and align
records to derive event sequence patterns.
Previous studies also investigate visual analytic methods to explore
and discover patterns from longitudinal data in clinical studies and
electronic medical records. DecisionFlow [19] allows users to ex-
plore multidimensional event sequences using multiple, coordinated
visual analytic systems. PhenoBlocks [17], PhenoStacks [16], and
PhenoLines [18] allow users to explore and compare cohorts based on
various measures. RetainVis, together with RetainEX, allows users to
understand how individual visits and categorical variables contribute to
making diagnostic risk predictions [30]. Clustervision [31] help users
to find informative cohorts of patients based on their common diseases,
treatments, diagnostic measures, and comorbidities. Bernard et al. de-
veloped and evaluated static dashboard network that can help users to
observe longitudinal changes of multiple patients [4]. Other studies
help users make sense of time-series health data, such as Stroscope [9],
TimeSpan [41], Marai et al. [43], and RegressionExplorer [12].
Though the previous approaches provide inspiring techniques, there
is no unified approach that integrates HMMs for exploring disease
progression patterns from longitudinal observational data.
3 DESIGN STUDY METHODS: USER, DATA, MODEL, TASKS
This section describes our design study by introducing characteristics of
domain experts, data, HMMs, and tasks and requirements that experts
intend to achieve through visualizations.
3.1 Design Study: Partnering with Research Groups
One of the greatest challenges in developing a visualization system for
medical application is not only to access appropriate datasets but also to
recruit expert groups. Our project started with a goal to create a visual
analytics tool that can be applied to various disease progression models.
We joined a collaboration project established in 2017 by JDRF and
their academic partners for computational modeling of T1D: the T1DI
(Type 1 Data Intelligence) study group. Many other research groups
with progression modeling studies for Parkinson’s and Huntington’s
disease were invited to collaborate and provide feedback.
3.2 User Characteristics: Clinical Researchers
Our primary target users are clinical researchers, such as physician sci-
entists and statisticians, who aim to investigate disease progression pat-
terns in observational data collected from clinical studies. Researchers
carefully select patients for long-term prospective clinical research in
order to better understand the characteristics that are associated with dis-
tinct disease progression patterns. A major goal of these investigators
is to formulate and test various known and unknown hypotheses related
to patients’ progression patterns, including how various progression
patterns relate to patients’ inherent characteristics, such as genetic traits,
ethnicity, and family history. In addition, researchers also speculate on
the relationship between the onset of diseases and other observed mea-
sures, such as lab tests, behavioral patterns (e.g., smoking), and growth
measures (e.g., height), collected from clinical studies. Domain experts
seek to build and refine multiple cohorts, each of which show common
characteristics, that lead to heterogeneous disease progression patterns,
and to find biomarkers related to the differences in the progression.
3.3 Data: Observational Data from Clinical Studies
Clinical researchers collect multivariate measures from subjects’ visits
through clinical studies. Patients’ visits may occur in equidistant or
irregular time intervals, depending on the study. For each visit, subjects
undergo lab tests and self-report their life-style patterns and environ-
mental exposures; these measures capture patient status that changes
over time (henceforth, ’observed variables’). Additionally, subjects are
also asked to report measures that do not change over time but may be
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Fig. 2: HMMs estimate a patient’s visit based on observed attribute
values chosen by users for training the model. The trained model
predicts the most probable state sequences for a patient and assigns
posterior probabilities for each visit.
related to the onset and progression of diseases (henceforth, ’static vari-
ables’). The observational data may contain missing and/or erroneous
data entries. Each dataset may contain longitudinal health records for
multiple subjects. Clinical researchers and statisticians often merge
datasets from multiple clinical studies. Therefore, observational data is
a form of temporal event sequence data, where each visit is associated
with a time stamp and contains a variety of health outcome measures.
3.4 Model: Hidden Markov Models and Variations
For disease progression modeling, we use continuous-time hidden
Markov models (CT-HMMs), which suits the longitudinal medical
records measured in non-equivalent time intervals between visits. Fig. 2
summarizes a diagram of a subject’s visit and its attribute values as
well as states, sequences, and posterior probabilities over states by a
pre-trained CT-HMM. In disease progression modeling, CT-HMMs,
trained by longitudinal patient records, assign (predict) a latent (hidden)
variable, called a “state,” for each visit based on associated observed
attribute values at the time. In addition, the trained model generates
posterior probability distribution over states for each visit.
The models are trained in an unsupervised manner. There are several
decisions for users to make prior to training: 1) the number of states;
2) a set of observed attributes used for training; 3) constraints on
progression steps (e.g., forward-only, forward-backward, no-skip). The
number of states are often determined based on the model fitness (e.g.,
log-likelihood measure) after multiple training phases. The set of
observed attributes are determined based on domain knowledge and
refined via multiple training iterations. Users can also set constraints
on the type of progression based on the disease. For more information
on Markov models, please see [5]. Our goal is to help users understand
the results of a trained model’s predictions on patients’ status that can
lead to better modeling decisions and clinically useful insights.
3.5 Tasks: Disease Progression Pathways
This section reports our target users’ tasks. We identified our target
tasks based on iterative discussions with domain experts, including
physician scientists and statisticians. We initially generated a variety of
low-level analytic questions and then abstracted to more generalizable,
high-level visualization tasks by following a design study methodol-
ogy [58, 60]. The following list shows the main user tasks.
T1: Understand the overall state transition patterns of all subjects:
Users gain an overview of state transition patterns. This includes, but
not restricted to, T1.1. viewing frequently occurring state transitions;
T1.2. viewing unexpected, infrequent state transitions; T1.3. viewing
state transition pathways (e.g., dwell time, progression pathways, sink
states); T1.4. viewing state-to-state bipartite transition network.
T2: Understand the characteristics of the states: Users seek to un-
derstand the average distributions over the observed variables, both used
and unused for training, per state. Understanding the characteristics
helps them interpret the states in a clinical perspective.
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Fig. 3: Feature Matrix shows mean values (blue to red; red being higher
values) for observed variables (rows) of states (columns). Users can
duplicate and fix the position for a set of variables (GAA 0, IA2 0,
IAA 0, ZnT8 0 at the top) by using the ’stick to the wall’ function.
T3: Construct and refine cohorts based on observed measures and
state transitions: Users want to build multiple cohorts by setting
filters with respect to various observed measures. They also want to
refine cohorts gradually by using state transitions and onset time.
T4: Compare multiple cohorts: Users want to quickly test hypothe-
ses about the relationship between onset time, observed measures, and
state transitions by building and comparing corresponding cohorts.
T5: View individual patients’ state transitions: Users want to view
and compare patients’ state sequences over a timeline. They want to
learn how similar or dissimilar selected subjects are in detail.
T6: View uncertainties in the model: Users want to understand dis-
ease progression pathways with their uncertainties. Users not only want
to understand the most probable sequence but also want to check the
posterior distributions over states per visit.
T7: Save and load intermediate analysis results: Experts often
spend days, weeks, and months interacting with the models, and dis-
cuss results with their colleagues. Therefore, users want to save their
intermediate results, such as cohorts, view settings, and sorting order
for views, so that they can resume their analyses from the last session.
Based on the derived tasks, we iteratively designed and assessed
multiple views. In the following section, we introduce the design of
DPVis and how each view and feature supports user’s analytic tasks.
4 DESIGN OF DPVIS
DPVis consists of seven view areas as Fig. 1 shows, and each has a dif-
ferent role. In particular, we developed multiple visualizations for two
main view areas in Fig. 1 (B) and (C): 1) Panel for Observed Attributes
and Panel for State Transitions. Users can toggle between visualiza-
tions depending on their tasks. All visualizations are connected, so
users can set filters using any view to update all views and the currently
selected cohort. In the following sections, we introduce each view of
DPVis and how these views can help users solve their tasks.
4.1 Static Variables Distribution View
Static Variables Distribution View shows a list of selected measures
that do not change over time in horizontal bar charts. Users can use
this view to show the general summary of subjects in terms of their
static measures, such as gender, race, and family history status. Using
this view, users can build cohorts based on factors related to subjects’
genetic characteristics and/or various environmental factors (T1). As
an example, for T1D, researchers hypothesize that children who are
breastfed have lower risk of developing the disease [15, 24]. Users
can click on the bar with ‘Y’ label on the ’bfever’ bar chart to cre-
ate a cohort with subjects who were breastfed (see Fig. 1 (A)). To
investigate further, users can add another filter by clicking on ‘Mother’
on ‘T1D reln2’, which refines the cohort to represent subjects who
received breastfeeding from diabetic mothers. Users can remove indi-
vidual filters by clicking on a specific bar, and they can remove all by
clicking an empty area in the background.
4.2 Distribution Views in Panel for Observed Attributes
Panel for Observed Attributes contains various views that present the
distribution of observed attributes that change their values over visits
(time). In this view, users can gain various insights from overview and
details about interaction between features, states, and time. Importantly,
this view can also visualize variables associated with a visit but was
(a) Distribution of GAA 0 in State-2 (b) Distribution of GAA 0 in State-7
Fig. 4: Feature Heatmap over Time shows density of attribute val-
ues over time. Above is an example for glutamic acid decarboxylase
autoantibodies (GAA 0) for states 2 and 7 in the T1D model.
not used for training the disease progression model. This enables users
to understand the characteristics of states based on all observed data.
4.2.1 Feature Matrix
Feature Matrix shows a grid layout in which a row represents an ob-
served attribute and a column represents a state learned by the model.
Each cell in this layout represents the mean of the attribute (row)
values of the visits that were predicted as the corresponding state (col-
umn). The diverging color map is used to map the range of minimum-
maximum values of each measure to the blue-red scale across the states.
This view is primarily used to understand distinctive characteristics of
different states with respect to the distribution over observed attribute
values (T2). During the design process, users requested the ability
to fix the heatmap of a set of selected measures below the state title
(‘stick to the wall’ as shown in Fig. 3). In this way, users can glance at
the fixed heatmap to understand the characteristics of states based on
the variables selected while interacting with other views. For instance,
in the nine-state model shown in Fig. 3, the states captures various
combinations of autoantibodies observed during patients’ visits. Users
can readily find that State-0 shows the state without any autoantibodies
present (low values in blue for all four attributes on top), and single-
autoantibody states (states 1,2,7,8). In addition, they can also see four
states with multiple autoantibodies (States 3 through 6). With these
in mind, users can interpret states in other views with respect to the
existence of single or multiple autoantibodies easily.
4.2.2 Feature Distribution
Users can choose to expand Feature Matrix to Feature Distribution,
which shows the distribution of each observed attribute in more detail.
Once expanded, the view shows a histogram in addition to mean and
standard deviation per cell in the grid layout. As Fig. 1 (B) shows, the
view repeats the same scale for all histograms for the same attribute in
order to enable comparison across states. Users can switch and toggle
back to fit the scale for each cell. The view also shows a dotted line
which represents a global mean value of the corresponding attribute
across states. In addition, users can check the number of missing values
per cell with a shaded bar above each cell. Users can also mouseover
on bars for distribution, bars for missing values, and dots for means to
read the numbers in a pop up. By leveraging the distributions shown
in this view, users can set a filter by drawing and moving brushes
per cell. By using this feature, users can interactively build more
sophisticated cohorts based on state-feature interactions. Once users
set filters, Feature Distribution overlays orange bars on top of the bar
chart, which indicate the distribution over attribute values per state
for the selected cohort. For instance, users may want to set a filter
for percentile BMI higher than 50% in State-0 in order to check if the
group shows any distinctive pathway trajectories in other views (T3).
4.2.3 Feature Heatmap over Time
Feature Heatmap over Time shows the trend of observed attributes
over time instead of states. We used 2D Kernel density estimation
with Gaussian kernel in order to compute the values for each cell
over 20×100 grid pixels; each cell size of the grid is determined in
proportion to users’ browser dimension and screen resolution. We map
attribute values to the RGB scale of white, yellow, and red so that the
darkest red represents the densest area in the plain of time (x-axis)
and the corresponding attribute (y-axis). The initial view shows an
overview of attributes values over time. Users can filter this view by
each state and compare the densities between multiple states. Users
can find interesting similarities between State 2 and State 7 over the
”stuck to the wall” Feature Matrix of the two states. As Feature Matrix
4
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Fig. 5: Feature over Time shows scatter plot of each visit’s (dot) value
of an observed variable (Y-axis) over time (X-axis). Above example
shows the trajectories for percentile BMI of a cohort, whose subjects
were breastfed with family history of diabetic mothers.
in Fig. 4 shows, users can find that these two seemingly similar states
represent two different states in terms of subjects’ age, where State 2 is
highly dense at the age in early ages around 40-50 months while State
8 is captured at ages between 120 and 160 months.
4.2.4 Feature over Time
Users can further investigate the details of the temporal trends of the
observed attributes using Feature over Time. This view shows a scat-
terplot, with optional connecting lines per subject, per attribute. Each
dot in a scatterplot represents a visit’s time (x-axis), attribute value
(y-axis), and state (color). The connecting lines between visits repre-
sent the trajectories of subjects over the attribute value range, and each
line segment connecting two dots are colored based on the slope of
the progression (red for positive; blue for negative). Using the previ-
ously created cohort (breastfed children with family history of diabetic
mothers), users can discover that subjects in this cohort show higher-
than-average BMIs, where a couple of subjects have obesity above 85th
percentile. This observation implies that these subjects were relatively
taller and/or heavier, throughout long-lasted observation periods. We
can also see hard cut-offs at month 24 because there is no agreed BMI
index for children under 24 months in clinical practice [14].
4.3 Pathway Views in Panel for State Transitions
Pathway views show various representations of state transition patterns
over sequences of visits or over time. In Panel for State Transitions,
users can choose among four views depending on the time intervals of
visits in observational data and their analytic goals.
4.3.1 Pathway over Observation
Pathway over Observation shows state transition patterns of multiple
subjects using the stacked sankey diagram approach. As Fig. 7 shows,
the view consists of two visual elements: nodes and paths. Nodes are
vertically stacked for each visit (x-axis), where each stack’s height
represents the number of subjects with the corresponding state at the
visit. Paths are drawn horizontally between two consecutive visits,
where each path connects a state (State-A) of the previous visit (Visit-0)
to another state (State-B) of the current visit (Visit-1). The thickness
of each path represents the number of subjects who transitioned from
State-A to State-B over the visits between 0 and 1. For an N-State
model, the view presents N nodes per visit and N2 paths between every
consecutive visit. Pathway over Observation allows users to gain an
overview of transition patterns by comparing the height of stacks over
visits first (T1). Then, users can check more details like incoming
subjects and outgoing subjects with respect to each stack or each visit.
We added multiple interaction techniques to the view so that users
can interactively ask questions related to state transitions more intu-
itively. First, we implemented Alignment Handle, which enables users
to vertically align stacked bars over visits with respect to a break point
between states per visit (e.g., between States 1 and 2 over all visits).
This view reconfigures the vertical arrangement of stacks so that users
can temporarily divide multi-state transitions into binary ones–above
and below Alignment Handle as Fig. 7b shows. For instance, users can
place Alignment Handle between two states, where the transition from
one state to another indicates irreversible progression from benign to
malignant clinical stages that can result in permanent disabilities. Users
can quickly glance over how stacks above Alignment Handle decrease
their length and in which visit the trend show a significant progression.
Users can also turn Pathway over Observation into a bipartite sankey
diagram. This view has only two stacked bars with paths between
(a) Pathway by Time Unit shows stacked
bars aligned at an anchor point between
states 3 and 4.
(b) Users set a filter by clicking on a node
(highlighted in orange) with State 4 at sub-
jects’ age between 4 and 5 years old.
Fig. 6: Pathway by Time Unit shows state transition pathways.
them (see Fig. 7c). This configuration simplifies the transition by only
showing the changeover from a start to an end. By using this view,
users can follow the state pathways between two nonconsecutive visits,
and answer questions like “what happen to 30 State-A subjects after 30
visits?” Users can reconfigure and switch to the new start and the end
visits to observe patterns between them during their analysis.
Users can also use Pathway over Observation to build cohorts. Users
can click a stack per visit and/or state transition paths between states
to filter subjects as Fig. 7a shows. This action propagates to all other
views; users can choose either to refresh Pathway over Observation
itself with the filtered subjects or to keep the current view. Regardless
of the choice, users are able to keep the current selection of node or
path highlighted in orange for their reference.
While the view is generally useful, Pathway over Observation is best
suited for clinical studies with regular visits separated by a consistent
interval between them. Some clinical studies start with a screening
visit, followed by weekly or bi-weekly sessions that assess patient
status using various lab tests. In this case, Pathway over Observation
reveals state sequences and allows researchers to view the development
of diseases in multiple cohorts. On the other hand, some other clinical
studies observe clinical sessions that are conducted in irregular visits.
In this case, Pathway over Observation may misguide or obscure pat-
terns because patients’ visits occur in irregular, inconsistent fashion; we
cannot align and aggregate state transitions by visit sequences. There-
fore, we need additional views that can be applied more generally to
clinical observations with irregular study visits.
4.3.2 Pathway by Time Unit
Pathway by Time Unit shows state transitions aggregated for a user-
selected time unit (e.g., hour, week, month). The visualization appears
as a counterpart to Pathway over Observation minus paths drawn be-
tween nodes. In Pathway by Time Unit, stacked bars are drawn over a
timeline. The width of each bar indicates a time unit, where it shows a
year in Fig. 6. The height of each stack in a bar represents the number
of subjects who were captured with the state during the time period.
Instead of paths drawn between nodes in Pathway over Observation,
Pathway by Time Unit shows state transitions with color gradients on
nodes. A node stack of the linear gradient of green (State-0) to red
(State-3) over a time unit (between ages 2 and 3) indicate the subjects
transition from 0 to 3 in their ages between 2 and 3. Using Pathway by
Time Unit, users can understand the prevalent states and their develop-
ment over time in subjects’ age or years preceding a certain medical
event by examining the stacked bars over time. Users can gain insights
into the general trend of when subjects start showing multiple autoan-
tibodies by aligning Pathway by Time Unit between State 3 and 4 as
Fig. 6a shows. In ages between 4 and 5, users can observe a signif-
icant decline in zero or single autoantibodies (States 0, 1, 2, 3) and
an increase in multiple autoantibodies (State-4). Users can also easily
observe study attrition for participants over 4 years old.
As Pathway over Observation provided, Pathway by Time Unit also
allows users to align state node stacks with respect to a break point using
Alignment Handle (see Fig. 6a). In addition, Pathway by Time Unit
also allows users to switch between user-defined time units. The time
variable can be defined various ways depending on analytic goals and
disease types. For instance, time can be defined as subjects’ biological
ages when users believe that the growth of biological development can
act as a significant confounding factor for disease progression, such as
T1D. In other cases, we can use years preceding each subject’s onset of
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(a) Pathway over Observation shows pathways for subjects
who started their first visit with State 0 (green); the first
node is highlighted in orange after users click to filter.
(b) Alignment Handle rearranges nodes and paths with
respect to a new anchor point (between states 3 and 4),
showing visits with States 1–3 decrease over visits.
(c) Users converted the view to only show start and end
nodes and the path between the two nodes, showing where
subjects starting with each state land in their final visits.
Fig. 7: Pathway over Observation uses the sankey diagram approach to summarize state transition pathways for subjects over observed visits.
motor impairment and/or cognitive disabilities in case of Huntington’s
disease. Users can also click on a node stack to set a filter based on
subjects’ state at a particular age (see Fig. 6b). As Fig. 6b shows,
subjects who were at State 4, showing multiple autoantibodies, tend to
maintain their status over time.
4.3.3 Pathway Waterfall
Pathway Waterfall shows subjects’ state transition patterns using paral-
lel beeswarm visualizations overlaid with individual subjects’ trajectory
lines. As Fig. 8 shows, we first divide the space into N vertical spaces,
each of which is dedicated to show a timeline for visits with N-th state.
Individual dots, colored corresponding to its state, are placed over the
timelines, and we preserve the timestamp without overlaid dots using
the beeswarm algorithm [13]. Then, we visualize trajectory lines for
individual subjects that follow the state transition pathways over time.
To reduce the clutter while maintaining the vertical position, we used a
modified version of force-edge bundling technique [25], where we only
bundle trajectories with the same state-to-state transitions at similar
times. To contrast the visual patterns of the trajectories more vividly,
we used a dark background color. A participant commented about the
intuitive pattern of Pathway Waterfall, “it looks like Mardi Gras beads
hanging on the wall. Easy to see where (in which state) they hook and
tangle up (congested departing/landing time periods per state).”
Using this view, users can view the distribution of visits over time
per state. In addition, they can also gain insights into the heterogeneous
state transition patterns over time by viewing bundled paths and follow-
ing the trajectories. As Fig. 8a shows the overview of state transition
pathways and the characteristics of states. The last three states appear
to be ”sink states”, in which subjects to tend to stay once they enter.
The major transition patterns occur between ages of 1 and 4, as one
can see from congested departing edges within the time period, which
implies the rapid development of various autoantibodies.
Using Pathway Waterfall, users can set filters on each timeline of a
state so that they can filter subjects that follow and stay at the states
within the user-defined time periods. This view is particularly useful to
disease progression pathways of subjects that share the same starting
and ending states but follow distinctive pathways. Fig. 8b shows disease
progression patterns of subjects who started with no autoantibodies
(State 0) before the age of 3 but ended up with all autoantibodies (State
6). Some subjects show drastic, rapid progression at their early ages,
but some others went through single- and double-autoantibodies states
(a) State Transition Chord Diagram shows
state transition patterns of all subjects
(b) Users set filters for a cohort of subjects
who were breastfed by diabetic mothers.
Fig. 9: State Transition Chord Diagram shows a summary of state
transitions between all pairs of consecutive states.
in the middle. Interestingly, it also shows two outliers, who passed
State-6 and transitioned back to single-autoantibody states (7 and 8).
4.3.4 State Transition Chord Diagram
State Transition Chord Diagram shows the overall state-to-state transi-
tion patterns over all consecutive pairs of observations from subjects
using a radial network diagram. The view can be used to understand
the overall frequency of state transitions. This view serves as an ex-
planatory summary of the state transition learned from the particular
setting of HMMs. It allows users to compare the number of visits per
state by viewing the size of the nodes (states) on the circular layout
and to compare the transitions between two states by the size of arcs
connecting two nodes inside the circular layout. In case of forward-
only progression models, one arc is drawn per a pair of different states.
As Figure 9a shows, the current model interprets that state transition
occurs rarely as the majority of transitions are no change shown as
self-directed arcs. On the other hand, a cohort with subjects who were
breastfed by diabetic mothers, as shown in Fig. 9b shows a greater
amount of States 1 and 3 and less States 4 and 8.
4.4 Frequently Occurring State Transition Pattern View
Frequently Occurring State Transition Pattern View shows a list of
frequently occurring state transition patterns mined from all consec-
utive observations. By running the BIDE algorithm [66] on subjects’
state sequences, we first generate the most frequently occurring state
sequence patterns. To avoid filling up the list with fine granular patterns,
we filtered top 50 patterns in terms of the number of unique subjects
with the corresponding pattern; we also do not take into account any
single-state patterns. Then, we list all patterns, where each pattern is a
row of state circles, in a vertical order, as shown in Fig. 10a. Inspired
(a) Pathway Waterfall shows state transition patterns of all subjects over 25 years. (b) Users filtered Pathway Waterfall by drawing two rectangular regions of interest
Fig. 8: Pathway Waterfall shows state transition pathways using parallel beeswarm plots and trajectory lines tied with force edge bundling. Each
beeswarm represents visits (dots) and their assigned states (color) over time (x-axis); paths show transitions between consecutive visits.
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(a) The view shows the top-50 most occur-
ring state sequence patterns.
(b) A new list of patterns from a cohort with
any siblings with diabetes.
Fig. 10: Frequently Occurring State Transition Pattern View shows the
result of pattern mining algorithm (BIDE) [66].
by Peekquence [34], we also visualized the frequency of the patterns as
a bar chart next to each pattern. Users can click on each pattern to filter
subjects who included the particular state transition patterns.
The view expand and introduce yet another list of patterns once
users set filters on any views as Fig. 10b shows. Then, the initial
list is squeezed to the left in order to make space for the new list of
pattern mining results on the right. The parallel lists of patterns show
differences in the ranked order of patterns mined from all subjects (left)
and selected cohort (right). If there are any patterns which were not
included in the initial list but occurred in the new list, we add a star
symbol to the left of each pattern to show the difference. For patterns
that exist in the initial list, users can hover the pattern to show a dotted
line between the same pattern in two different lists to check how the
rank of the pattern differs in two subject cohorts.
4.5 Subject Timeline
Subject Timeline shows individual subjects’ observations over time. In
this section, we introduce two components of the view: 1) Subject List
View; and 2) Dual Kernel Densities View.
4.5.1 Dual Kernel Densities View
Dual Kernel Densities View shows the two independent 1-D Kernel
Density (KD) diagrams, each with increasing y-axis (density) in the
opposite direction, upward and downward, respectively, as Fig. 11
shows. The KD above the timeline shows the density of time at the onset
(e.g., diagnosis of Chronic Obstructive Pulmonary Disease (COPD)).
Subsequently, the KD below the timeline can be freely chosen by users,
with the dropdown menu on the top-right corner, among the secondary
onset variables (e.g., the first failure in motor, cognitive, functional
tests for Huntington’s Disease). Each KD includes an arrow indicating
the mean age of its onset for subjects. Once users set filters, the KDs
introduce and overlay brighter KDs inside, which indicate KDs for the
selected cohort. Dual Kernel Densities View also introduces additional
dotted lines, indicating the mean values of the cohort. Users can also
draw a rectangular region over the timeline, which sets a filter for
subjects who had the onset at the age between the user-defined range.
Fig. 11 suggests that the subjects’ mean diagnosis age is at 8-9 years
old with a peak around age 12 and a long tail towards older ages. By
looking at the dual KDs, it seems that the mean difference between
the diagnosis (red KD above) and the first onset of seroconversion
(light purple below) is about three years; the difference increases for a
cohort (dotted lines, darker purple below, and orange above) with being
breastfed, which is consistent with the prior studies [15, 24]
4.5.2 Subject List View
Subject List View provides a list of subjects’ observations as dots
(visits) over a timeline. Each dot represents a visit, which are color-
coded based on the corresponding state. For each subject, we draw a
narrow, red rectangle below a dot for a visit with the onset of the disease
and an asterisk symbol above a visit with the onset of the secondary
variable (e.g., initiation of medication in Parkinson’s disease). The
initial order of subjects are in the order of patient index code, but the list
brings patients within a selected cohort to the top once users set filters.
In Subject List View, users can view the posterior distribution over N
states as a pie chart. By observing how slices of pies change their values
over time, users can inspect the detailed disease progression of a subject
including the model’s confidence of state assignment (T6). Users can
hover to open a popup view that shows the posterior distributions
of all visits for a specific subject. Fig. 11 shows the selected list
of patients who were never breastfed. Most dots present full circles
Fig. 11: Subject Timeline shows 1) Dual Kernel Densities View and
2) Subject List View. Dual Kernel Densities View overlays additional
dual Kernel Density Diagrams for a selected cohort, and Subject List
View highlights subjects in the cohort. Users open a popup to view
posterior distributions over 9 states for a subject with three visits.
(dominant with a slice), which show model’s confidence in the state
assignments. However, a subject on the popup shows evenly-spread
posterior distrbutions over nine states for the last two visits, which
signify uncertainties of state assignment for those visits. As it turns out
in the view, the subject shows seroconversion (purple star above pie)
and diagnosis (red underline below pie) at the same time under 1 year
old, which is why the model thinks of the visits as uncertain or outliers.
4.6 State Sequence Query Builder
State Sequence Query Builder is a way users can freely define and refine
queries to create a cohort based on state transition patterns (T3). Using
a drag-and-drop interaction, users can freely build, edit, and remove
patterns. The view initially shows an empty canvas with horizontally
arranged state nodes with an additional dummy node (in total, N+1
nodes). As users start dragging a node, a green area appears, which
indicates an area in which users can drop the node to build a pattern.
Once the number of nodes on canvas increases above one, links are
drawn connecting the nodes. Every node and edge has its own proper-
ties shown with labels, which can also be edited on a popup window.
Each node has three properties: 1) time, 2) node at, and 3) posteriors.
Using these three properties, users can further refine a search query
per node with respect to the time range of the node, whether the node
is at the beginning, middle, end, or anywhere, and the top-2 posterior
distributions. Each edge between two nodes has two properties: 1)
the maximum time between nodes and 2) the sequential order of the
two nodes. Users can set the maximum allowed time between two
nodes and determine whether the two states need to be consecutive,
not consecutive, or either. The dummy node is used when users do
not intend to specify any state for the visit. Once users are satisfied
with the configuration of patterns to search for, users can hit the “Filter
by Pattern” below to filter based on the pattern. Users can continue
to refine patterns after observing the results. Fig. 12 shows a pattern
with two nodes: State-2 and State-5. The pattern includes specific
configuration: 1) State-2 occurs between age between 0 and 85 months
as the beginning state for the subject; 2) State-3 occurs between age
between 114 and 287 months as the ending state for the subject; 3) both
states are assigned with posterior probabilities greater than .75 at least.
Fig. 12: State Sequence Query Builder allows users to build and refine
state transition patterns. Users can adjust filtering criteria (e.g., time of
visit) for each node and edge by opening context menu.
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Fig. 13: Comparison Mode shows comparison between two cohorts: 1)
subjects who were seroconverted with GADA (glutamic acid decarboxy-
lase autoantibodies; light blue) and 2) those who were seroconverted
with IAA (Insuilin Autoantibodies; light yellow).
4.7 Cohort View and Comparison Mode
In this view, users manage cohorts built during their analysis. They can
also trigger Comparison Mode between selected cohorts from this list.
4.7.1 Cohort View
Cohort View shows a list of subject cohorts that have been built and
kept by the user (see top right corner in Fig. 1). Using this view, users
can easily switch between cohorts. The height of each bar corresponds
the relative number of subjects within each cohort. The title can be
modified with free text so that users can keep short description about
the cohort. As users hover each bar, a popup view shows the description
of filters, namely a list of pairs of an attribute name and its value range,
used to create the corresponding cohort. The small icon below each bar
allows users to ‘clone’ the set. Using this function, users can branch
out new analytic path from an existing cohort while keeping its original.
Users can also import cohorts from existing static variables by choosing
one variable on the dropdown menu at the top-right corner. Users can
also save the cohorts as a file along with other configurations like the
sorting order of observed variables in views of Panel for Observed
Attributes. They can save the current progresses or load previously
created cohorts anytime to continue their analyses in another day or to
share their progresses with other colleagues (T7).
4.7.2 Comparison Mode
Once users have more than two cohorts in Cohort View, users can
trigger Comparison Mode with selected cohorts. As Fig. 13 shows,
this selection turns all views into Comparison Mode. Static Variables
Distribution View changes the existing bars transparent in the back-
ground, and introduces additional bars per category or bin of each
bar chart; the newly introduced bars, each representing a cohort with
assigned color as shown as light blue and light yellow in Fig. 13. It also
opens Feature Distribution in Panel for Observed Attributes. Feature
Distribution removes all existing bars for distributions, except for the
mean dots and error bars. It introduces additional dots, color-coded for
corresponding cohorts, separated horizontally at the vertical position
for the mean values of the corresponding states per cohort. Comparison
Mode disables Frequently Occurring State Transition Pattern View and
Subject Timeline while maximizing the viewport of Panel for State
Transitions. Pathway by Time Unit show cohorts in a vertical list so
that users can compare multiple cohorts’ state transition trajectories.
Using Comparison Mode, users can compare state transition pathways
and their interaction with various static and observed attributes for
multiple cohorts (T4). Fig. 13 shows Comparison Mode between sub-
jects seroconverted with GADA against subjects seroconverted with
IAA, where GADA and IAA are two distinct autoantibody types. They
show distinct pathways as users can view the prevalence of State 1
(yellow stacks in Pathway by Time Unit) in the IAA cohort (yellow
background). The IAA cohorts show higher-than-average percentile
height and weight particulary for States 6 and 7 in Feature Distribution,
which occur at ages after 10 years old in Pathway by Time Unit; the
accelerated growth pattern is supported by Lamb et al. [35].
5 CASE STUDY: CLINICAL STUDIES OF TYPE 1 DIABETES
In this section, we introduce a case study that demonstrates how DPVis
can help users explore disease progression pathways. Together with two
physician scientists, we developed the following use case of DPVis by
analyzing observational data from clinical studies of T1D. We illustrate
this story with a fictitious character, Amy, a clinical investigator in T1D
research who seeks to understand the disease progression patterns from
168 subjects, who were diagnosed with T1D, using observations from
clinical studies: DIPIS [28] and DAISY [56].
Amy decided to model the subjects’ progression data using CT-
HMM. Since there is no prior research in using DPM for subjects with
T1D, she trained models with a range of parameters, primarily the num-
ber of states, from 2 to 20. She had a hypothesis about which variable
sets could best characterize T1D development: autoantibodies. For
training the autoantibody model, she used three observation variables,
all markers of disease progression: glutamate decarboxylase autoanti-
body (GADA), insulin autoantibody (IAA), and islet autoantigen-2 au-
toantibody (IA2A) (More studies on autoantibodies can be found [64]).
To test her hypothesis, she trained the two different models respectively
with a range of states (N = [2, 20]). After testing the models with
multiple rounds of cross-validations, she narrowed down to the best
performing model based on the log-likelihood scores on the validation
dataset: the 9-state autoantibody (AAB) model.
Amy started exploring the 9-state autoantibody model (see Fig. 1),
first considering the overview provided by Feature Matrix, Pathway
by Time Unit, and State Transition Chord Diagram. She found that
the model provides balanced distribution over 9 states, according to
State Transition Chord Diagram. She opened Feature Matrix in Panel
for Observed Attributes to interpret the list of observed attributes that
distinguish one state from another. Using the ranked order of measures,
she found that the model accurately captures the development of all
three autoantibodies over time as seen in Fig. 1. She also found it very
interesting to see zinc transporter 8 autoantibodies (ZnT8A) tended
to correlate with state assignment, even though it was not included
as an observed variable used for the model training. She checked the
data collection and learned that ZnT8A was measured only if another
autoantibody (GADA, IAA, and IA2A) was positive: a measurement
bias. She used the ‘stick to the wall’ feature, selecting GADA, IAA,
IA2A, and ZnT8A to be always on top below the state column in Panel
for Observed Attributes for easy reference. This view summarizes the
states’ characteristics with respect to the three observation variables
(GADA, IAA, and IA2A), starting from no autoantibody (State-0), to
single autoantibody (States 1, 2, 7, and 8), to double autoantibodies
(States 3, 4, 5), and triple autoantibodies (State 6), as Fig. 3 shows.
Amy found that the states represent unique combinations of the three
autoantibodies, except States 2 and 7, which are single-autoantibody
states with GADA. She turned Feature Matrix to Feature Heatmap over
Time to compare states, 2 and 7, and found that State-7 occurs at older
ages (140 months) than State-2, as Fig. 4 shows.
With the 9-state model, Amy started exploring the disease progres-
sion patterns of 168 subjects. It is known that T1D follows three clinical
stages: Stage 1, two or more autoantibodies but normal blood glucose;
Stage 2, two or more autoantibodies and high blood glucose; Stage 3,
clinical diagnosis of diabetes (see more details in Insel et al. [27]). Amy
started with the following questions. Can we observe similar trends
from subjects? Are there unexpected, extraordinary subjects who do
not follow the three-stage progression? Can we find pre-stage patterns
even before subjects develop two or more autoantibodies in Stage 1?
What are the characteristics of the patterns?
To follow state transition patterns of subjects with two or more au-
toantibodies at one point, Amy created three cohorts by filtering based
on States 3, 4, and 5, which have two unique autoantibodies. Using
Frequently Occurring State Transition Pattern View, Amy checked the
most frequent patterns of subjects after States 3, 4, and 5; then, she
opened Pathway Waterfall to understand their pathways. For the State-3
cohort, there were 31 subjects in total. Among 31 subjects, 17 subjects
stayed in double autoantibodies (States 3, 4, 5), and 10 subjects pro-
gressed to triple autoantibodies (States 6); the rest of 4 subjects evolved
to a single antibody state (State 7 or 8). Among 56 subjects in the State-
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4 cohort, 49 subjects stayed in double (States 4,5, or 6) or transitioned
to triple autoantibodies; 7 subjects went to a single antibody state (State
8). Among 20 subjects in the State 5 cohort, 15 subjects stayed in
double or triple autoantibodies (States 5 or 6); 5 subjects went to a
single autoantibody state (State 8). In conclusion, DPVis allowed her
to visually confirm that subjects generally follow the three-stage model,
where they maintain multi-autoantibody status and showed increasing
trends in HbA1c (reflecting elevated blood sugar levels) toward the last
visit, where the subject is diagnosed, in Feature over Time. There were
also notable exceptions who went from multiple to single autoantibody
states (16 subjects). Furthermore, she also finds that State 3 and State 5
cohorts are relatively young at diagnosis (mean age = 7.2 and 7.9 years
old) in comparison to State 4 cohorts (mean age = 9.9 years old). This
led Amy to believe that there seems to be heterogenous progression
patterns that follow the 3-stage model, but there are also exceptions.
She further set a filter using a static variable, called ‘seroconverted after
6 years old’, on top of the State 4 cohorts. She realized that all subjects
who ended up at State 8 (single-antibody) showed a sharp increase of
ZnT8A after 6 years old. Amy speculated that ZnT8A will be another
observed variable for a new CT-HMM model if she can collect more
observations on ZnT8A without measurement bias.
Following subjects’ trajectories, Amy found that there are many
subjects who were continuously assigned State 0 (no autoantibodies)
for all visits, yet they were diagnosed with T1D. To investigate the
cohort closer, she searched using a visit sequence pattern starting and
ending with State 0 with no time restriction in State Sequence Query
Builder. The query returned seven subjects, who were diagnosed around
90 months (7.5 years) old, according to Dual Kernel Densities View.
Among those seven, four appeared to have seroconverted before six
years old in Static Variables Distribution View, so she clicked to set a
filter based on “seroconverted before six.” In Feature over Time, four
out of seven subjects did not show any presence of GADA or IA2A
throughout their observation periods, but showed brief presence of IAA
in one visit which disappeared in the subsequent visit. Amy speculated
two interpretations. First, the negative autoantibody at the last visit may
be measurement error. Second, the subjects may represent an endotype
characterized by factors that are not captured in our data [2]. Amy was
intrigued and decided to request more information about them.
6 DISCUSSION
In this section, we discuss implications of DPVis, lessons learned from
our study, and provide our thoughts for future work.
6.1 Design Study Reflection: Working in a Triad on DPVis
An important key to success of design study is to effectively facili-
tate communication between experts in their domains, mainly health
professionals, statisticians, and visualization experts. By combining
the pieces from the triad of experts, we can build an effective visual
analytics application. Though it is essential for the experts to carefully
evaluate each other’s inputs, it is very challenging due to the knowl-
edge gaps between domains. What facilitates effective communication
between experts in different fields can be the visualization itself [33].
Throughout meetings, experts discussed over DPVis, which resulted
in several changes to try out in the next phase. Therefore, what makes
a visual analytics tool interpretable and engaging for users is how ef-
fectively the representations facilitate communication and new insights
among the team. DPVis was used to translate a fundamental question
from health professionals about HMMs, “what is a state and how does
it differ from clinical stages?” As Section 5 revealed, DPVis allowed
our team to understand how multiple states may fit a clinical stage and
to hypothesize more granular states that can describe within and outside
clinical stages. An expert also reported that Pathway Waterfall allowed
him to make sense of the overall scale and dimension of patients’ visits
over time. In the meetings, we gained numerous insights into the data
aided by the various visualizations presented in this paper.
6.2 Cohort Building Using Multiple Views
Our goal for this study is to help physician scientists to discover hetero-
geneous disease progression patterns and their interaction with various
patient factors. Thus, it is inevitable to include multiple views that
provide different perspectives of state transition. We provided four dif-
ferent views in Panel for State Transitions. Each view shows its unique
visual interpretation of subjects’ trajectories. Given heterogeneous
conditions of observational data, multiple views can avoid unwanted
bias from a view with its specific aggregation of diverse patterns.
Physician scientists often test hypotheses by comparing different pa-
tient cohorts. The cohorts are often challenging to describe when using
sophisticated criteria for grouping patients; DPVis provides various
ways to build cohorts using all views and allows direct construction
and refinement of queries using State Sequence Query Builder, setting
intuitive filtering actions on any views. The flexible methods for con-
structing filters was useful for our experts to formulate and test their
hypotheses. The features blends well with users’ analytic workflow,
where they define and express cohorts and test their hypotheses by
comparing the patterns out of those cohorts. Cohort View enables users
to maintain and share such cohorts with colleagues as they iteratively
refine their analysis. Using these features, we generated clinically use-
ful insights for potential future publication in clinical journals. A future
work is to investigate intuitive ways to build cohorts, which include
drawing expected patterns over visualizations like AxiSketcher [32].
6.3 Embracing HMMs for Visual Analytics
In our study, we find that HMMs provide various outcomes that can
be useful for visual analytics applications. In particular, HMMs allow
us to discover latent (hidden) states that are associated with observed
attributes in an unsupervised manner. Clinical researchers desire to
learn about how diseases go through various states (stages), to dis-
cover biomarkers (observed attributes) that can affect or characterize
the progression, and to use them to detect disease earlier in patients.
HMMs provide us with the explainable states and their transitions with
posterior probabilities–which informs users of the model’s confidence.
More importantly, it is essential to use visual analytics for users to
explore and compare various modeling options and outcomes. Our case
study demonstrates that users can intuitively make sense of the model
outcomes and make informed decisions on what actions they need to
take, e.g., gather more data, change the number of states, or choose a
new set of observed attributes for modeling. A future direction is to
build visual analytics applications that enable users to compare multiple
training instances with different parameter combinations.
7 CONCLUSION
In this work, we conducted a design study with physician scientists,
statisticians, and visualization experts to develop a visual analytics
application for exploring disease progression pathways and their in-
teraction with various measures. As a result, we developed DPVis,
which seamlessly incorporates HMMs and provides intuitive views
and interactive features that facilitate users to develop and test hy-
potheses by iteratively constructing multiple cohorts based on state
transitions and distributions over multiple measures. With a case study,
we demonstrate the usefulness of the application to derive clinically
useful insights using HMMs on observational data from clinical studies
of T1D. Our collaborators have been continuously researching disease
progression patterns for Huntington’s disease and Parkinson’s disease.
In future work, we plan to extend DPVis to observational data from
clinical studies of other chronic diseases (e.g., Alzheimer’s Disease).
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